Vitamin a derivative combined with immunotherapy shows promise in early lung cancer trial
NCT ID NCT04919369
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a combination of all-trans retinoic acid (ATRA), a substance made from vitamin A, and the immunotherapy drug atezolizumab in people with advanced non-small cell lung cancer that has spread or come back. The main goal is to find the safest dose and understand side effects. The study involves 18 participants who have already tried standard treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
All-trans retinoic acid (ATRA) and atezolizumab (Tecentriq)
What this could lead to
If it works, this could point toward a new combination treatment for advanced lung cancer that helps the immune system fight the tumor more effectively.
What could go wrong
This is a very early phase I trial with only 18 participants, so the main goal is safety, not effectiveness. The combination may cause side effects or not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States